Replies to post #39205 on CYduct Diagnostics Inc (CYDX)

[Ask kicker]

I agree wholeheartedly. Here are some theories about why they increased the A/S:

1) From what I understand from an earlier post, the SteriTap is being manufactured in Europe. This allows the device to become available for CE Mark approval. To expedite the MammoView to sale outside of the US, they are likely positioning themselves to also produce the MammoView in Europe. As a result, need working capital to get production ramped up and started.
2) A new distribution partner may require specific amounts of inventory to move SNDY products. As a result, they need additional capital to meet the inventory requirements.
3) A partnership between SNDY and some other company is in the works and therefore required the adjustment in A/S to follow-through with this partnership.
4) A large order may have already been received and SNDY needs the funding to build the units to complete the order.

Not sure if any of the above theories will become fact. Just thinking. -IMO